Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Project Grant - PA: Pandemic Preparedness and Health Emergencies Research

University of British Columbia

$100,000.00

Optimization of next-generation RNA vaccines for pandemic preparedness

FY 2022-23

Summary
Messenger RNA (mRNA) technology has revolutionized our ability to develop safe, effective vaccines in a short time frame and at a large scale. Although the mRNA vaccines have had an incredible impact on the COVID-19 pandemic, there is still room for improvement. For example, we now know that the side effects are directly proportional to the dose of RNA, which motivates minimizing the required dose. Furthermore, the duration of immunity of the current mRNA vaccines is relatively short lived, requiring boosters approximately every six months. Finally, a certain proportion of the population has anaphylactic reactions to certain vaccine components, including polyethylene glycol (PEG). In this research program, we aim to develop RNA vaccines that improve upon the current mRNA vaccines and would be rapidly deployable in the event of an outbreak or pandemic. Self-amplifying RNA (saRNA) is the next generation of mRNA and the focus of my research program; it is a special type of mRNA that is able to replicate once it gets into a cell and requires a much lower dose. Like mRNA, saRNA requires a formulation that protects it from degrading and delivers it safely and consistently into cells. We hypothesize that by optimizing lipid nanoparticle formulations, which are the current state of the art technology for administering mRNA, and the dosing interval, we can identify lead clinical candidates for more potent and safer RNA vaccines. First, we will optimize LNP formulations that more efficiently the target immune cells that make a robust vaccine response. We will also optimize the dosing regimen to enable creation of a stronger immune 'memory' and longer lasting protection. Finally, we will engineer new LNP formulations that do not contain PEG so that more of the population is eligible to receive RNA vaccines. These vaccines can be applied to outbreaks, including COVID, seasonal viruses such as influenza, and future pandemics and will improve the health of millions of Canadians.
Program
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
473356
Name
Blakney Anna
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Infection and Immunity
Theme2
Biomedical
Prcname2
Pharmaceutical Sciences
Projecttitle
Optimization of next-generation RNA vaccines for pandemic preparedness
Programtype2
Operating Grants
Orgnameinp2
University of British Columbia
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant - PA: Pandemic Preparedness and Health Emergencies Research
Keyworddelim
Humoral Immunity; Lipid Nanoparticles; Messenger Rna; Nanomedicine; Pandemic Preparedness; Polyethylene Glycol; Reactogenicity; Rna; Self-Amplifying Rna; Vaccines
Abstract
Messenger RNA (mRNA) technology has revolutionized our ability to develop safe, effective vaccines in a short time frame and at a large scale. Although the mRNA vaccines have had an incredible impact on the COVID-19 pandemic, there is still room for improvement. For example, we now know that the side effects are directly proportional to the dose of RNA, which motivates minimizing the required dose. Furthermore, the duration of immunity of the current mRNA vaccines is relatively short lived, requiring boosters approximately every six months. Finally, a certain proportion of the population has anaphylactic reactions to certain vaccine components, including polyethylene glycol (PEG). In this research program, we aim to develop RNA vaccines that improve upon the current mRNA vaccines and would be rapidly deployable in the event of an outbreak or pandemic. Self-amplifying RNA (saRNA) is the next generation of mRNA and the focus of my research program; it is a special type of mRNA that is able to replicate once it gets into a cell and requires a much lower dose. Like mRNA, saRNA requires a formulation that protects it from degrading and delivers it safely and consistently into cells. We hypothesize that by optimizing lipid nanoparticle formulations, which are the current state of the art technology for administering mRNA, and the dosing interval, we can identify lead clinical candidates for more potent and safer RNA vaccines. First, we will optimize LNP formulations that more efficiently the target immune cells that make a robust vaccine response. We will also optimize the dosing regimen to enable creation of a stronger immune 'memory' and longer lasting protection. Finally, we will engineer new LNP formulations that do not contain PEG so that more of the population is eligible to receive RNA vaccines. These vaccines can be applied to outbreaks, including COVID, seasonal viruses such as influenza, and future pandemics and will improve the health of millions of Canadians.
Competitiondate
202209
Approvedterm2
1 yr 0 mth
Pinamesdelim
Blakney, Anna
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~